Introduction: The overall survival in patients with gliomas has not significantly increased in the modern era, despite advances such as immunotherapy. This is in part due to their notorious ability to suppress local and systemic immune responses, severely restricting treatment efficacy.
Methods: We have reviewed the preclinical and clinical evidence for immunosuppression seen throughout the disease process in gliomas.